Reports

Federal money to fight the opioid crisis nearly doubled in the last two years, according to a national think tank’s new report analyzing that funding.

To address the growing misuse and diversion of prescription drugs, the Ohio General Assembly adopted legislation in 2004 authorizing the State of Ohio Board of Pharmacy to create a Prescription Monitoring Program (PMP), known as the Ohio Automated Rx Reporting System (OARRS). Established in 2006, OARRS collects information on all outpatient prescriptions for controlled substances and two non-controlled substances (gabapentin and naltrexone) dispensed by Ohiolicensed pharmacies and personally furnished by Ohio prescribers. This data is reported every 24 hours and is maintained in a secure database. Drug wholesalers and manufacturers are also required to submit information monthly on all controlled substances and gabapentin sold to an Ohio licensed pharmacy or prescriber.

The following items are recommendations from the Governor's Cabinet Opiate Action Team of information that should be included to meet the health instruction requirement focused on “Prescription opioid abuse prevention, with an emphasis on the prescription drug epidemic and the connection between prescription opioid abuse and addiction to other drugs, such as heroin.”

In 2017, the United States recorded 70,237 drug overdose deaths; among these, 47,600 (67.8%) involved an opioid, and 28,466 (40.5%) involved a synthetic opioid other than methadone (e.g., fentanyl and tramadol) (1). During 2013–2017, sustained growth in the availability of illicitly manufactured fentanyl (IMF) drove large increases in overdose deaths involving a synthetic opioid other than methadone (1). Specifically, the number of drug products obtained by law enforcement that were submitted for laboratory testing and tested positive for fentanyl (fentanyl submissions) increased rapidly, especially in the Midwest and Northeast U.S. Census regions.

The CDC has identified 220 counties at risk of outbreaks of HIV and/or hepatitis C as a result of the opioid epidemic. These represent only the top 5% of counties in the nation based on 6 factors assessed. Health officials responsible for these counties should be particularly sensitive to ensure targeted, evidence-based interventions and services are available.

Kaiser Family Foundation provides reliable state health data, including opioid overdose deaths by race and ethnicity. This data set is particularly helpful for understanding how opioid overdoes death rates among different races and ethnic groups differ between states.

From 1999-2017, almost 400,000 people died from an overdose involving any opioid, including prescription and illicit opioids. This rise in opioid overdose deaths can be outlined in three distinct waves.

The number of prescription opioid-related overdose deaths excluding involvement of fentanyl declined almost 28 percent since 2011, and to an eight-year low. Prescription opioid-related overdose deaths also accounted for a substantially smaller percentage of all unintentional overdose deaths in 2017 (10.8 percent) than in 2011 (40.9 percent). The decline in prescription opioid deaths corresponded with Ohio’s efforts to reduce the prescription opioid supply available for misuse and diversion, which has included shutting down pill mills, putting in place prescribing guidelines, strengthening prescription drug monitoring, stepping up enforcement efforts and developing new regulations for drug wholesalers.